The permeability glycoprotein (P-GP) - A threat to effective drug therapy?

Indian Drugs

Volumn 43, Issue 8, 2006, Pages 609-615

  Dwibhashyam, V S N M ^a   Vijayaralna, J ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Drug therapy; P glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLYCOPROTEIN; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; SPHINGOLIPID ACTIVATOR PROTEIN 2;

DRUG THERAPY; PERMEABILITY; PHARMACOKINETICS;

EID: 46349105219     PISSN: 0019462X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Jeevan K.R.and Patrick S.J. Intestinal drug transporters: In vivo function and clinical importance. Curr. Drug Met. 2004, 5. 114-115.
2. Pankajavalli R. The role of P-glycoprofein in the Blood- Brain Barrier. Einstein Quart. J. Biol. Med. 2003,19,160-165.
3. Thiebut F., Tsuruo T., Hamada H., Gottesman M.M. and Pastan I. Cellular localization of the muitidrug resistance gene product P-giycoprotein in normal human tissues. Proc. Natl. Acad. Sol. USA. 1987, 84, 7735-7738.
4. Lauretta Chan M.S., Simon L and Barry H.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavaiiabiiity. Eur. J. Pharm. Sci. 2004, 21. 25-51.
5. Klimecki W.T., Futscher B.W., Grogan T.M. and Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994, 83, 2451-2458. (Pubitemid 24135836)
6. Varma M.V.S., Yasvanth A., Chinmoy S.D. and Ramesh P. P-glycoprolein Inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 2003, 48, 347-359. (Pubitemid 36945333)
7. Higgins C.F. and Gottesman M.M. Is the multidrug transporter a flippase? Trends Biol. Sci. 1992, 17, 18-21.
8. Loo T.W. and David C.M. Do drug substrates enter the common drug binding pocket of P-glycoprotein through "gates"? Biochem. Biophys. Res. Communications. 2005, 329, 419-422. (Pubitemid 40311762)
9. Gottesman M.M. and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62. 385-427. (Pubitemid 23237876)
10. Loo T.W. and Clarice D.M. Molecular dissection of the human multidrug resistance P-glycoprotein. Biochem. Cell Biol, 1999,77,11-23. (Pubitemid 29342829)
11. Schinkel A.H. P-glycoprolein, a gatekeeper in the bloodbrain barrier. Adv. Drug Del. Rev. 1999, 36, 179-194.
12. Kim R.B., Fromm M.F.,Wandei C., Leake B., WoodA.J.J. and Roden D.M. The drug transporter p-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998,101, 289-294. (Pubitemid 28067324)
13. Elizabeth C.M., Sandrine M., Dirk-Jan. Van der S., De Boer A.G., Annie D., Serge B. and William O. In vitro and in vivo investigations on fluoroquinolones: effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 2000,12, 85-93.
14. Evans A.M. Influence of dietary components on the gastrointestinal metabolism and transport of drugs.Ther. Drug Monlt. 2000, 22, 131-136. (Pubitemid 30083114)
15. Panwala C.M., Jones J.C. and Viney J.L. A novel model of inflammatory bowel disease; mice deficient for the multiple drug resistance gene, mdr 1a,spontaneously develop colitis. J. Immunol. 1998, 161, 5733-5744. (Pubitemid 28519142)
16. Rodriguez-Ibanez M., Nalda-Molina R., Montalar- Montero M., Bermejo M. V., Merino V. and Garrigues, T.M. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: invitro and insitu inhibition studies. Eur. J. Pharm. Biopharm. 2003, 55, 241.
17. Williams W.C. and Sinco P.J. Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Del. Rev. 1999, 39, 211-238.
18. Chiou W.L., Chung S.M. and Wu T.C. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm. Res. 2000, 17, 205-208.
19. Chiou W.L., Chung S.M. and Wu T.C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 2001, 39, 93-101. (Pubitemid 32208536)
20. Varma M.V.S., Mahua S., Namitha K. and Ramesh P. Ph dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs. 1.Simultaneous determination of quinidine and permeability markers in rat in-situ perfusion samples. J. Chromatography B. 2005, 816, 243-249. (Pubitemid 40143512)
21. Manaf S., Olof B. and Ursula H.B. The role of Pglycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur. J. Pharm. Sci. 2001,14, 21-27.
22. Akira N., Hiroshi S., Masako Oda, MasahikoT. and Bruce A.J. Region-dependent disappearance of vinblastine in rat small intestine and characterization of its Pglycoprotein- mediated efflux system. Eur. J. Pharm. Sci. 2000,11,317.
23. Sparreboom A., Van A.J., MayerU., Schinkel A.H., Smit, J.W., Meijer D.K.F., Borst P., Nooijen W.J., Beijnen J.H. and Van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 1997, 94, 2031-2035. (Pubitemid 27113956)
24. Philip B.S., Jay G.T., Robert C.A., Norman Ho F.H. and Allen H.R, In-vitro permeability of peptidomimetic drugs: the role of polarized efflux pathways as additional barriers to absorption. Adv. Drug Del. Rev. 1997,23,148-149.
25. Bruce A.J. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti HIV drugs. Adv. Drug Del. Rev. 1999, 39,105.
26. Evan K.D., Christine H., Dale W. and Pam Sheffels. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.Clin. Pharmacol. Ther. 2003, 74, 543.
27. Andrew C. The influence of P-gp on morphine transport in caco-2 cells. Comparison with paclitaxel. Eur. J. Pharmacol. 2002, 440, 7.
28. Leslie B.Z., Chi-Yuan W., Mary H.F. and Vincent W.J. Intestinal drug metabolism and antitransport process: A potential paradigm shift in oral drug delivery. J. Control. Rel. 1996, 39. 142.
29. Alex S. and Kees N. Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist. Updates. 2000. 3, 359.
30. Candace G.L. and Gary P.M. Drug Transport at the Blood-Brain Barrier and the choroids plexus. Curr. Drug Met. 2004, 5, 95-108.
31. Jiunn Lin H. Role of pharmacokinetics in the discovery and development of indinavir. Adv. Drug Del. Rev. 1999, 39, 45.
32. Jashvant U.D., Amber D. and Shashivijay. Placental Drug Transporters. Curr. Drug Met. 2004,5,128.
33. Fumihiko U,. Hitomi T., Hirotami M., Shigaeki Yanai Kiyomi T., Hitoo N., Takeshi U., Takanori N., Michihiko K., Hisakazu O. and Yasufumi S. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. 408, 2000, 8-9.
34. Cristina S., Stephane C., Paul Tulkens M. and Francoise, V.B. influence of P-glycoprotein and IVIRP effiux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria I monocytogenes or Staphylococcus aureus. J. Antimicrob. Chemother. 2003, 51,1172.
35. Van Montfoort J.E., Hagenbuch B., Groothuis G.M.M., Koepsell H., Meier P.J. and Meijer D.K.F. Drug Uptake Systems in Liver and Kidney. Curr. Drug Met. 2003,4, 204.
36. Smit J.W., Schinkel A.H., Weert B. and Meijer D.K.F. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr la and mdr 1b genes have been disrupted. Br. J. Pharmacol. 1998, 124, 416.
37. Fardel O., Lecureur V. and Guillouzo A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 1996, 27,1283-1291. (Pubitemid 26419684)
38. Hoffmeyer S., Burk O., Von Richter O., Arnold H. P. and Brock-moller J. Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in-vivo. Proc. Natl. Acad. Sci. USA. 2000, 97, 3473-3478. (Pubitemid 30183327)
39. Kristin W., Anita M., Gerd F., Manfred K., Reinhard O., Peter Fritz. Oliver V., Rolf W., Thomas H., Kauffmann Dieter, Bernd, Kroemer K. and Werner S. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 2000, 68, 353.
40. Monica M. Manuela M., Rosati A. Flora B., Luigi C., Tullio G. and Giuliana D. Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK, cells. Eur. J. Pharmacol. 2004, 483, 19-28. (Pubitemid 38056600)
41. Milchell A., Melissa A., Barbara D., Haehner-Daniels, Stephen D., The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther., 2001,69,114.
42. Werner S., Stephan A., Andrea P., Ute Hecker, Michael Z., Gerd F., Wieland M., Rolf Warzok, Eike S., Bernhard S., Bernd T., Ingolf C. and Heyo Kroemer K. Effect of levothyroxine administration on intestinal P-glycoprotein expression: Consequences for drug disposition. Clin. Pharmacol. Ther. 2002, 72, 263.
43. Donat D., Bruno S., Gerd A., Kullak U., Katharina M., Hans C., Peter J. and Karin F. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 2000,68,601.
44. Varma M.V.S., Sateesh K., Yasvanth A., Amit J., Anandbabu D., Anurag S.,Thomas N.S., Pillai O., Pradeep S., Rajesh G., Shrutidevi A., Vinod N. and Ramesh P. Biopharmaceutical Classification System: A Scientific Frarnework for Pharmacokinetic Optimization in Drug Research. Curr. Drug Met. 2004, 5, 375-388. (Pubitemid 39276602)
45. Osten J., Parviz B.M., Mattias P., Roger H. and Kjell G. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem. Pharmacol. 1999, 58, 1801.
46. Celine V., Soraya S., Hakima E.M., Reinhold K., Ulrich B., Liliane D., Patrice J., Christian F., Germain T. and Laurent B. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 2003, 73, 51.
47. Jurgen D., Heike G., Gert F., Michael T.,Christoph B. and Jorg H. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol. 1999, 57,1147.
48. Tara L., Peter S.C.,Jenny, Hardison, Sharon D.B., Remo, G., Gianfranco B., Severo S. and Lawrence H.L. Inhibition of human multidrug resistance P-glycoprotein 1 by analogues of a potent δ-opioid antagonist. Brain Res. 2001, 902, 131-134.
49. Bhagwant D., Joseph P.Y.K. and James P.E. Effects of nonionic surfactants on membrane transporters in caco- 2 cell monolayers. Eur. J. Pharm. Sci. 2002, 16, 237-238.
50. Yu-li Lo. Relationships between the hydrophiliclipophilic balance values of pharmaceutical excipients and their multidrug modulating effect in caco-2 cells and rat intestines. J. Control. Rel. 2003, 90, 37-48. (Pubitemid 36588877)
51. Iwao O., Pierre-Yves B., Craig T., Pera P. and Ralph, J.B. New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells. Bioorg. Med. Chem. Letters. 1998, 8,189-194. (Pubitemid 28037182)
52. Yiu-Cheong W.J., Wang-Fun F., Jin-Xia Z., Chang-Hang L., Hoi-Lung K., Meng-Su Y., Ding Li and Hon-Yeung C. Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radixpeucedani. Eur. J. Pharmacol. 2003, 473, 9-17. (Pubitemid 36851623)
53. Songyot A., Pranee L., Melissa M.S., Suresh V.A. and Pornngarm L. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 2002, 64, 573-582.
54. Laurent B., Celine V., Reinhold K., Ulrich B., Martine L., Patrice J. and Christian Funck-Brentano. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 2001,70,311-315.
55. Tomomi I., Fumihiko U., Noriko K., Satoshi M., Yukihiro S., Mikihiko N., Takashi T., Hisakazu O. and Yasufumi S. Inhibition of P-glycoprotein by orange juice components, polymethoxyflavonesin adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Letters. 2000,160, 21-28.
56. Shapiro A.B. and Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem. Pharmacol. 1997, 53, 587-596. (Pubitemid 27149553)
57. Jan H.M., Mirte M.M., Kruijtzer C.M.F., Bardelmeijer, Van O., Schinkel A.H. and Beijnen J.H. Modulation of oral bioavaiiability of anticancer drugs; from mouse to man. Eur. J. Pharm. Sci. 2000,12.106.
58. Potschka H., Maren F. and Wolfgang L. P-glycoproteinmediated efflux of phenobarbltal, lamotrigine and felbamate at tfie biood-brain barrier: evidence from microdialysis experiments in rats. Neuroscience Letters. 2002, 327, 173-176. (Pubitemid 34756625)
59. Yasuhisa K., Michinori M., Kei T., Tohm S., Noriyuki K., Teruo A. and Kazumitsu U. ATP Hydrolysis-dependent multidrug efflux transporter: MDRI/P-glycoprotein.Curr. Drug Met. 2004, 5.1.
60. Raderer M. and Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer. 1993. 72. 3553-3563. (Pubitemid 24000587)
61. Kohji T. Mikio K. Yusuke T. Junko F. Tosfiiyuki S. and Katsuhiko O. Interaction of digoxin with antihypertensive drugs via MDR1. Life Sciences. 2002, 70.1491-1500.